SCHEMBL2376591

SCHEMBL2376591

COc1cccc(C(=O)C2CC=COC2=O)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
PARP1 P09874 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 2/20 0.43
PKM P14618 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM2B Q8NHM5 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
FAAH O00519 1/20 0.41
CNR2 P34972 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
CTNNB1 P35222 2/20 0.41
WNT3A P56704 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376978 0.80 CES2 (0.53) CES2CES1PARP1L3MBTL1ALDH1A1
SCHEMBL2376977 0.77 CES2 (0.53) CES2CES1PARP1L3MBTL1ALDH1A1
SCHEMBL13872879 0.75 HPGD (0.52) CES2CES1PARP1L3MBTL1ALDH1A1
SCHEMBL31636008 0.74 CES2 (0.65) CES2CES1PARP1NPC1RAB9A
SCHEMBL7309424 0.74 CES2 (0.65) CES2CES1PARP1NPC1RAB9A
SCHEMBL29466669 0.71 CES2 (0.53) CES2CES1PARP1L3MBTL1ALDH1A1
SCHEMBL18360283 0.71 KDM2B (0.62) CES2CES1PARP1L3MBTL1ALDH1A1
SCHEMBL12247723 0.71 L3MBTL1 (0.50) CES2CES1PARP1L3MBTL1ALDH1A1
SCHEMBL6208933 0.69 CES2 (0.57) CES2CES1PARP1NPC1RAB9A
SCHEMBL30009669 0.69 CES2 (0.57) CES2CES1PARP1L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 CES2 4145/4885CES1 1519/4885PARP1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.